IFNG and cancer: Although exogenous IFN-γ treatment confers limited results in clinical therapy due to its side effects on systemic inflammation, concurrently reversing production of IFN-γ in tumor-suppressing cells and signaling of IFN-γ in cancer cells can be utilized to evaluate the therapeutic efficacy after anticancer treatment, particularly in immune checkpoint-based therapy.